FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 336:1416-1422 May 15, 1997 Number 20 Next

	Full Text PDF Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Germ-line mutations in the BRCA1 and BRCA2 genes predispose women to breast cancer. BRCA1 mutations are found in approximately 12 percent of women with breast cancer of early onset, and the specific mutation causing a deletion of adenine and guanine (185delAG), which is present in 1 percent of the Ashkenazi Jewish population, contributes to 21 percent of breast cancers among young Jewish women. The contribution of BRCA2 mutations to breast cancer of early onset is unknown.

Methods Lymphocyte specimens from 73 women with breast cancer diagnosed by the age of 32 were studied for heterozygous mutations of BRCA2 by a complementary-DNA–based protein-truncation assay, followed by automated nucleotide sequencing. In addition, specimens from 39 Jewish women with breast cancer diagnosed by the age of 40 were tested for specific mutations by an allele-specific polymerase chain reaction.

Results Definite BRCA2 mutations were found in 2 of the 73 women with early-onset breast cancer (2.7 percent; 95 percent confidence interval, 0.4 to 9.6 percent), suggesting that BRCA2 is associated with fewer cases than BRCA1 (P = 0.03). The specific BRCA2 mutation causing a deletion of thymine (6174delT), which is found in 1.3 percent of the Ashkenazi Jewish population, was observed in 1 of the 39 young Jewish women with breast cancer (2.6 percent; 95 percent confidence interval, 0.09 to 13.5 percent), indicating that it has a small role as a risk factor for early-onset breast cancer. Among young women with breast cancer, there are BRCA2 mutations that cause truncation of the extreme C terminus of the protein and that may be functionally silent, along with definite truncating mutations.

Conclusions Germ-line mutations in BRCA2 contribute to fewer cases of breast cancer among young women than do mutations in BRCA1. Carriers of BRCA2 mutations may have a smaller increase in the risk of early-onset breast cancer.

Source Information

From the Center for Cancer Risk Analysis and the Massachusetts General Hospital Cancer Center, Charlestown, Mass. (M.K., S.S.-A., M.G.F., D.J.M., H.U., K.J.I., D.A.H.); the Divisions of Biostatistics (D.M.F.) and Hematology–Oncology (D.A.H.), Massachusetts General Hospital and Harvard Medical School, Boston; the Department of Clinical Oncology, Tohoku University, Sendai, Japan (A.S., C.I., R.K.); and the Division of Pediatric Hematology–Oncology, University of Texas Southwestern Medical Center, Dallas (A.B.).

Address reprint requests to Dr. Haber at the Laboratory of Molecular Genetics, Massachusetts General Hospital Cancer Center, CNY 7, Bldg. 149, 13th St., Charlestown, MA 02129.

Full Text of this Article

This article has been cited by other articles:

• Stachelek, G. C., Dalal, S., Donigan, K. A., Campisi Hegan, D., Sweasy, J. B., Glazer, P. M. (2010). Potentiation of Temozolomide Cytotoxicity by Inhibition of DNA Polymerase {beta} Is Accentuated by BRCA2 Mutation. Cancer Res. 70: 409-417 [Abstract] [Full Text]  
• Sardanelli, F., Podo, F., D'Agnolo, G., Verdecchia, A., Santaquilani, M., Musumeci, R., Trecate, G., Manoukian, S., Morassut, S., de Giacomi, C., Federico, M., Cortesi, L., Corcione, S., Cirillo, S., Marra, V., For the High Breast Cancer Risk Italian Trial (HIB, (2007). Multicenter Comparative Multimodality Surveillance of Women at Genetic-Familial High Risk for Breast Cancer (HIBCRIT Study): Interim Results. Radiology 242: 698-715 [Abstract] [Full Text]  
• Simeone, A.-M., Deng, C.-X., Kelloff, G. J., Steele, V. E., Johnson, M. M., Tari, A. M. (2005). N-(4-Hydroxyphenyl)retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated breast cancer cells. Carcinogenesis 26: 1000-1007 [Abstract] [Full Text]  
• Claus, E. B., Petruzella, S., Matloff, E., Carter, D. (2005). Prevalence of BRCA1 and BRCA2 Mutations in Women Diagnosed With Ductal Carcinoma In Situ. JAMA 293: 964-969 [Abstract] [Full Text]  
• Kim, S-W, Lee, C S, Fey, J V, Borgen, P I, Boyd, J (2005). Prevalence of BRCA2 mutations in a hospital based series of unselected breast cancer cases. J. Med. Genet. 42: e5-e5 [Full Text]  
• Pal, T., Permuth-Wey, J., Holtje, T., Sutphen, R. (2004). BRCA1 and BRCA2 Mutations in a Study of African American Breast Cancer Patients. Cancer Epidemiol. Biomarkers Prev. 13: 1794-1799 [Abstract] [Full Text]  
• Evans, D G R, Eccles, D M, Rahman, N, Young, K, Bulman, M, Amir, E, Shenton, A, Howell, A, Lalloo, F (2004). A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. J. Med. Genet. 41: 474-480 [Abstract] [Full Text]  
• Choi, D. H., Lee, M. H., Bale, A. E., Carter, D., Haffty, B. G. (2004). Incidence of BRCA1 and BRCA2 Mutations in Young Korean Breast Cancer Patients. JCO 22: 1638-1645 [Abstract] [Full Text]  
• Thull, D. L., Vogel, V. G. (2004). Recognition and Management of Hereditary Breast Cancer Syndromes. The Oncologist 9: 13-24 [Abstract] [Full Text]  
• Domchek, S. M., Eisen, A., Calzone, K., Stopfer, J., Blackwood, A., Weber, B. L. (2003). Application of Breast Cancer Risk Prediction Models in Clinical Practice. JCO 21: 593-601 [Abstract] [Full Text]  
• Scheuer, L., Kauff, N., Robson, M., Kelly, B., Barakat, R., Satagopan, J., Ellis, N., Hensley, M., Boyd, J., Borgen, P., Norton, L., Offit, K. (2002). Outcome of Preventive Surgery and Screening for Breast and Ovarian Cancer in BRCA Mutation Carriers. JCO 20: 1260-1268 [Abstract] [Full Text]  
• Martin, A.-M., Blackwood, M.A., Antin-Ozerkis, D., Shih, H.A., Calzone, K., Colligon, T.A., Seal, S., Collins, N., Stratton, M.R., Weber, B.L., Nathanson, K.L. (2001). Germline Mutations in BRCA1 and BRCA2 in Breast-Ovarian Families From a Breast Cancer Risk Evaluation Clinic. JCO 19: 2247-2253 [Abstract] [Full Text]  
• Chaudhuri, S., Cariappa, A., Tang, M., Bell, D., Haber, D. A., Isselbacher, K. J., Finkelstein, D., Forcione, D., Pillai, S. (2000). Genetic susceptibility to breast cancer: HLA DQB*03032 and HLA DRB1*11 may represent protective alleles. Proc. Natl. Acad. Sci. USA 97: 11451-11454 [Abstract] [Full Text]  
• PLASCHKE, J., COMMER, T., JACOBI, C., SCHACKERT, H. K, CHANG-CLAUDE, J. (2000). BRCA2 germline mutations among early onset breast cancer patients unselected for family history of the disease. J. Med. Genet. 37: 17e-17 [Full Text]  
• Lehman, T. A., Haffty, B. G., Carbone, C. J., Bishop, L. R., Gumbs, A. A., Krishnan, S., Shields, P. G., Modali, R., Turner, B. C. (2000). Elevated Frequency and Functional Activity of a Specific Germ-Line p53 Intron Mutation in Familial Breast Cancer. Cancer Res. 60: 1062-1069 [Abstract] [Full Text]  
• Lal, G., Liu, G., Schmocker, B., Kaurah, P., Ozcelik, H., Narod, S. A., Redston, M., Gallinger, S. (2000). Inherited Predisposition to Pancreatic Adenocarcinoma: Role of Family History and Germ-Line p16, BRCA1, and BRCA2 Mutations. Cancer Res. 60: 409-416 [Abstract] [Full Text]  
• Spain, B. H., Larson, C. J., Shihabuddin, L. S., Gage, F. H., Verma, I. M. (1999). Truncated BRCA2 is cytoplasmic: Implications for cancer-linked mutations. Proc. Natl. Acad. Sci. USA 96: 13920-13925 [Abstract] [Full Text]  
• Haber, D. A. (1999). Breast Cancer in Carriers of BRCA1 and BRCA2 Mutations: Tackling a Molecular and Clinical Conundrum. JCO 17: 3367-3370 [Full Text]  
• Phillips, K.-A., Andrulis, I. L., Goodwin, P. J. (1999). Breast Carcinomas Arising in Carriers of Mutations in BRCA1 or BRCA2: Are They Prognostically Different?. JCO 17: 3653-3663 [Abstract] [Full Text]  
• Barton, M. B., Harris, R., Fletcher, S. W. (1999). Does This Patient Have Breast Cancer?: The Screening Clinical Breast Examination: Should It Be Done? How?. JAMA 282: 1270-1280 [Abstract] [Full Text]  
• Bell, D. W., Wahrer, D. C. R., Kang, D. H., MacMahon, M. S., FitzGerald, M. G., Ishioka, C., Isselbacher, K. J., Krainer, M., Haber, D. A. (1999). Common Nonsense Mutations in RAD52. Cancer Res. 59: 3883-3888 [Abstract] [Full Text]  
• Warner, E., Foulkes, W., Goodwin, P., Meschino, W., Blondal, J., Paterson, C., Ozcelik, H., Goss, P., Allingham-Hawkins, D., Hamel, N., Di Prospero, L., Contiga, V., Serruya, C., Klein, M., Moslehi, R., Honeyford, J., Liede, A., Glendon, G., Brunet, J.-S., Narod, S. (1999). Prevalence and Penetrance of BRCA1 and BRCA2 Gene Mutations in Unselected Ashkenazi Jewish Women With Breast Cancer. JNCI J Natl Cancer Inst 91: 1241-1247 [Abstract] [Full Text]  
• Peto, J., Collins, N., Barfoot, R., Seal, S., Warren, W., Rahman, N., Easton, D. F., Evans, C., Deacon, J., Stratton, M. R. (1999). Prevalence of BRCA1 and BRCA2 Gene Mutations in Patients With Early-Onset Breast Cancer. JNCI J Natl Cancer Inst 91: 943-949 [Abstract] [Full Text]  
• Tang, N. L. S., Pang, C.-P., Yeo, W., Choy, K.-W., Lam, P. K., Suen, M., Law, L. K., King, W. W. K., Johnson, P., Hjelm, M. (1999). Prevalence of Mutations in the BRCA1 Gene Among Chinese Patients With Breast Cancer. JNCI J Natl Cancer Inst 91: 882-885 [Full Text]  
• de Bock, G., Vlieland, T. V., Hageman, G., Oosterwijk, J., Springer, M., Kievit, J (1999). The assessment of genetic risk of breast cancer: a set of GP guidelines. Fam Pract 16: 71-77 [Abstract] [Full Text]  
• Lynch, H. T., Casey, M. J., Shaw, T. G., Lynch, J. F. (1998). Hereditary Factors in Gynecologic Cancer. The Oncologist 3: 319-338 [Abstract] [Full Text]  
• Newman, B., Mu, H., Butler, L. M., Millikan, R. C., Moorman, P. G., King, M.-C. (1998). Frequency of Breast Cancer Attributable to BRCA1 in a Population-Based Series of American Women. JAMA 279: 915-921 [Abstract] [Full Text]  
• Malone, K. E., Daling, J. R., Thompson, J. D., O'Brien, C. A., Francisco, L. V., Ostrander, E. A. (1998). BRCA1 Mutations and Breast Cancer in the General Population: Analyses in Women Before Age 35 Years and in Women Before Age 45 Years With First-Degree Family History. JAMA 279: 922-929 [Abstract] [Full Text]  
• Couch, F. J., Hartmann, L. C. (1998). BRCA1 Testing--Advances and Retreats. JAMA 279: 955-957 [Full Text]  
• Orlando, R., Birkmeyer, J. D., Welch, H. G., Meijer, W. J., van Lindert, A. C.M., Grann, V., Whittemore, A. S., Schrag, D., Weeks, J. C. (1997). Risk of Breast Cancer in Carriers of BRCA Gene Mutations. NEJM 337: 787-789 [Full Text]  
• (1997). What to Make of the Genetic Picture of Breast Cancer?. JWatch Women's Health 1997: 5-5 [Full Text]  
• (1997). *BRCA* GENES AND BREAST CANCER RISK. JWatch General 1997: 3-3 [Full Text]  
• Healy, B. (1997). BRCA Genes -- Bookmaking, Fortunetelling, and Medical Care. NEJM 336: 1448-1449 [Full Text]  
• Schrag, D., Kuntz, K. M., Garber, J. E., Weeks, J. C. (1997). Decision Analysis -- Effects of Prophylactic Mastectomy and Oophorectomy on Life Expectancy among Women with BRCA1 or BRCA2 Mutations. NEJM 336: 1465-1471 [Abstract] [Full Text]